2023-10-31T19:54:17
Italy-based Alfasigma has agreed to acquire the Jyseleca (filgotinib) business from Belgian biotech Galapagos for €170 million.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-27T15:37:00
Sponsored by IMA Pharma
2025-11-20T15:00:00
Sponsored by Rapid Micro Biosystems
2025-09-24T15:24:00
Sponsored by Lonza
2025-10-08T07:00:00
Sponsored by Entegris
2025-07-16T11:00:00
Sponsored by USP
Site powered by Webvision Cloud